4120 Stock Overview
A pharmaceutical company, develops and manufactures drugs worldwide.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 1/6 |
Financial Health | 2/6 |
Dividends | 1/6 |
Orient EuroPharma Co., Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | NT$47.95 |
52 Week High | NT$55.90 |
52 Week Low | NT$35.65 |
Beta | 0.42 |
11 Month Change | 9.47% |
3 Month Change | 16.24% |
1 Year Change | 14.30% |
33 Year Change | 14.99% |
5 Year Change | -21.00% |
Change since IPO | 280.80% |
Recent News & Updates
Recent updates
Here's Why Orient EuroPharma (GTSM:4120) Has A Meaningful Debt Burden
Apr 04Is Orient EuroPharma Co., Ltd.'s (GTSM:4120) 3.3% Dividend Worth Your Time?
Mar 04A Look At Orient EuroPharma's (GTSM:4120) Share Price Returns
Feb 10Is Orient EuroPharma Co., Ltd.'s (GTSM:4120) Recent Performancer Underpinned By Weak Financials?
Jan 22We Think Orient EuroPharma (GTSM:4120) Can Stay On Top Of Its Debt
Jan 04A Look At The Fair Value Of Orient EuroPharma Co., Ltd. (GTSM:4120)
Dec 17Are Dividend Investors Getting More Than They Bargained For With Orient EuroPharma Co., Ltd.'s (GTSM:4120) Dividend?
Nov 29Shareholder Returns
4120 | TW Pharmaceuticals | TW Market | |
---|---|---|---|
7D | -4.1% | -1.6% | -4.6% |
1Y | 14.3% | 9.8% | 31.4% |
Return vs Industry: 4120 exceeded the TW Pharmaceuticals industry which returned 9.8% over the past year.
Return vs Market: 4120 underperformed the TW Market which returned 31.4% over the past year.
Price Volatility
4120 volatility | |
---|---|
4120 Average Weekly Movement | 4.5% |
Pharmaceuticals Industry Average Movement | 4.5% |
Market Average Movement | 4.7% |
10% most volatile stocks in TW Market | 8.6% |
10% least volatile stocks in TW Market | 2.2% |
Stable Share Price: 4120 has not had significant price volatility in the past 3 months.
Volatility Over Time: 4120's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1982 | n/a | Peter Tsai | www.oepgroup.com |
Orient EuroPharma Co., Ltd., a pharmaceutical company, develops and manufactures drugs worldwide. Its prescription medicines include cardiovascular, metabolism, neurology, obstetrics and gynecology, respiratory, andrology, immunology, antibiotic, and anti-cancer drugs. The company also provides nutrition and baby care products, such as milk and nutritional supplements under the Karihome, Babecare, and Ostricare brands; and healthcare supplements, such as thermal water for the treatment of oral and periodontal diseases under the Buccotherm name.
Orient EuroPharma Co., Ltd. Fundamentals Summary
4120 fundamental statistics | |
---|---|
Market cap | NT$4.16b |
Earnings (TTM) | NT$26.28m |
Revenue (TTM) | NT$4.55b |
158.3x
P/E Ratio0.9x
P/S RatioIs 4120 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
4120 income statement (TTM) | |
---|---|
Revenue | NT$4.55b |
Cost of Revenue | NT$2.39b |
Gross Profit | NT$2.15b |
Other Expenses | NT$2.13b |
Earnings | NT$26.28m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 0.30 |
Gross Margin | 47.33% |
Net Profit Margin | 0.58% |
Debt/Equity Ratio | 101.5% |
How did 4120 perform over the long term?
See historical performance and comparison